Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model

Fig. 4

Vaccine effector T-cell responses analyzed by subset depletions. Mice were vaccinated three times at 1 week intervals and then challenged with a lethal dose (5 × 104) of B16F10 cells. T-cell subsets were depleted one day prior to challenge, on day of challenge, and 7 days post challenge. Quality of the depletions was assessed by flow cytometric analysis of peripheral blood lymphocytes on days 0 and 8 or 10. a Representative flow cytometry plots shown depicting CD4 and CD8 expression gated on overall lymphocytes from blood collected at day 10 post challenge. b Tumor growth regression plot from day 6 to 13 post challenge, assessed by mixed effects regression. c Tumor size at day 13 post challenge, with significance assessed by ANOVA. All data are from two independent experiments of 4–5 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page